N6-methyladenosine (m6A)
(Synonyms: N6-甲基腺苷; 6-Methyladenosine; N-Methyladenosine) 目录号 : GC14698
N6-methyladenosine (m6A)是腺苷的潜在激动剂,ED50值为17250nM。
Cas No.:1867-73-8
Sample solution is provided at 25 µL, 10mM.
N6-methyladenosine (m6A) is a potential agonist of adenosine with an ED50 value of 17250nM[1]. N6-methyladenosine is the methylation occurring at the N6 position of adenine, and is the most common internal modification on eukaryotic mRNA[2]. N6-methyladenosine regulates gene expression, thereby controlling a series of processes such as cell self-renewal, differentiation, invasion and apoptosis[3]. A global decrease in N6-methyladenosine (m6A) results in double-stranded RNA (dsRNA) formation and a profound cell-intrinsic interferon response[4]. The changes in N6-methyladenosine levels are closely related to the clinical and pathological features of gastrointestinal tumors and liver cancer. N6-methyladenosine has become a potential diagnostic and prognostic marker or a promising therapeutic target[5].
References:
[1] Ribeiro J A, Sebastião A M. On the type of receptor involved in the inhibitory action of adenosine at the neuromuscular junction[J]. British journal of pharmacology, 1985, 84(4): 911.
[2] Chen M, Wong C M. The emerging roles of N6-methyladenosine (m6A) deregulation in liver carcinogenesis[J]. Molecular cancer, 2020, 19(1): 44.
[3] He L, Li H, Wu A, et al. Functions of N6-methyladenosine and its role in cancer[J]. Molecular cancer, 2019, 18(1): 176.
[4] Guirguis A A, Ofir-Rosenfeld Y, Knezevic K, et al. Inhibition of METTL3 results in a cell-intrinsic interferon response that enhances antitumor immunity[J]. Cancer Discovery, 2023, 13(10): 2228-2247.
[5] Zhu D H, Su K K, Ou-Yang X X, et al. Mechanisms and clinical landscape of N6-methyladenosine (m6A) RNA modification in gastrointestinal tract cancers[J]. Molecular and Cellular Biochemistry, 2024, 479(7): 1553-1570.
N6-methyladenosine (m6A)是腺苷的潜在激动剂,ED50值为17250nM[1]。作为腺嘌呤N6位点的甲基化修饰,N6-methyladenosine是真核生物mRNA中最常见的内源性化学修饰[2]。N6-methyladenosine通过调控基因表达,参与细胞自我更新、分化、侵袭和凋亡等一系列生物学过程[3]。整体性N6-methyladenosine水平降低会导致双链RNA(dsRNA)形成并引发强烈的细胞内在干扰素反应[4]。N6-methyladenosine水平变化与胃肠道肿瘤和肝癌的临床病理特征密切相关,已成为潜在的诊断预后标志物和治疗靶点[5]。
Cas No. | 1867-73-8 | SDF | |
别名 | N6-甲基腺苷; 6-Methyladenosine; N-Methyladenosine | ||
化学名 | (2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(methylamino)-9H-purin-9-yl)tetrahydrofuran-3,4-diol | ||
Canonical SMILES | CNC1=C(N=CN2[C@@]3([H])[C@@](O)([H])[C@@](O)([H])[C@@](O3)([H])CO)C2=NC=N1 | ||
分子式 | C11H15N5O4 | 分子量 | 281.27 |
溶解度 | ≥ 12.2mg/mL in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 3.5553 mL | 17.7765 mL | 35.553 mL |
5 mM | 711.1 μL | 3.5553 mL | 7.1106 mL |
10 mM | 355.5 μL | 1.7777 mL | 3.5553 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet